E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER)
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 18, 2016
December 29, 2022
34160d8d-51b7-47bd-a753-e6ad93180322
Related Documents
Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry
Guidance DocumentSeptember 30, 2016Center for Drug Evaluation and Research
Contents of a Complete Submission for the Evaluation of Proprietary Names
Guidance DocumentApril 11, 2016Center for Drug Evaluation and Research
E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers
Guidance DocumentJuly 19, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox